dc.contributor.author | Rongsen-Chandola, Temsunaro | en_US |
dc.contributor.author | Strand, Tor A. | en_US |
dc.contributor.author | Goyal, Nidhi | en_US |
dc.contributor.author | Flem, Elmira | en_US |
dc.contributor.author | Singh Rathore, Sudeep | en_US |
dc.contributor.author | Arya, Alok | en_US |
dc.contributor.author | Winje, Brita Askeland | en_US |
dc.contributor.author | Lazarus, Robin | en_US |
dc.contributor.author | Shanmugasundaram, Elango | en_US |
dc.contributor.author | Babji, Sudhir | en_US |
dc.contributor.author | Sommerfelt, Halvor | en_US |
dc.contributor.author | Vainio, Kirsti | en_US |
dc.contributor.author | Kang, Gagandeep | en_US |
dc.contributor.author | Bhandari, Nita | en_US |
dc.date.accessioned | 2015-03-24T14:57:58Z | |
dc.date.available | 2015-03-24T14:57:58Z | |
dc.date.issued | 2014-08-11 | eng |
dc.identifier.issn | 0264-410X | |
dc.identifier.uri | https://hdl.handle.net/1956/9630 | |
dc.description.abstract | Interference from transplacental and breast milk antibodies may impede the performance of oral livevaccines. The effect of breastfeeding on the immunogenicity of Rotarix®, a two-dose oral monova-lent rotavirus vaccine, was examined in a community-based trial in New Delhi, India. Four hundredmother–infant pairs were randomized into two equal groups. Infants were aged 6–7 weeks at enroll-ment. Mothers were encouraged to either breastfeed or to withhold breastfeeding during the 30 minprior to and after each vaccine dose was administered. We collected blood specimens from infants atenrollment and 4 weeks after the second vaccine dose. Blood and breast milk specimens were obtainedfrom mothers at baseline and breast milk specimens were collected at the time of the second vaccinedose. Seroconversion was defined as infant serum anti-VP6 IgA antibody level of ≥20 IU/mL 4 weeksafter the second vaccine dose and a ≥4-fold rise from baseline. There was no difference in the propor-tion who seroconverted between the two groups (26% vs 27%; p = 0.92). The levels of infant serum IgA,maternal serum and breast milk IgA and IgG anti-rotavirus antibodies predicted the anti-rotavirus IgAlevel in infants at end-study and explained approximately 10% of the variability of the immune response(r2= 0.10, p < 0.001). In this population, the immune response to Rotarix®was not enhanced by withholding breastfeedingaround the time of vaccination. Maternal anti-rotavirus antibodies explained little of the variability in theimmune response to the vaccine. Factors other than maternal anti-rotavirus antibodies probably explainwhy infants in low-and middle-income settings respond poorly to live oral rotavirus vaccines. | en_US |
dc.language.iso | eng | eng |
dc.publisher | Elsevier | eng |
dc.rights | Attribution-NonCommercial-NoDerivs CC BY-NC-ND | eng |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | eng |
dc.subject | rotavirus | eng |
dc.subject | Rotarix® | eng |
dc.subject | Vaccine | eng |
dc.subject | immune response | eng |
dc.subject | withhold breastfeeding | eng |
dc.subject | encouraged breastfeeding | eng |
dc.title | Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants | en_US |
dc.type | Peer reviewed | |
dc.type | Journal article | |
dc.date.updated | 2015-03-04T10:23:05Z | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2014 Published by Elsevier Ltd. | |
dc.identifier.doi | https://doi.org/10.1016/j.vaccine.2014.04.078 | |
dc.identifier.cristin | 1152461 | |
dc.source.journal | Vaccine | |
dc.source.40 | 32 | |
dc.source.14 | Suppl. 1 | |
dc.source.pagenumber | A134-A139 | |
dc.relation.project | Norges forskningsråd: 223269 | |
dc.subject.nsi | VDP::Medical sciences: 700::Health sciences: 800::Preventive medicine: 804 | eng |
dc.subject.nsi | VDP::Medical sciences: 700::Health sciences: 800::Health service and health administration research: 806 | eng |
dc.subject.nsi | VDP::Medical sciences: 700::Basic medical, dental and veterinary sciences: 710::Medical immunology: 716 | eng |
dc.subject.nsi | VDP::Medical sciences: 700::Health sciences: 800::Community medicine, social medicine: 801 | eng |
dc.subject.nsi | VDP::Medisinske fag: 700::Helsefag: 800::Forebyggende medisin: 804 | nob |
dc.subject.nsi | VDP::Medisinske fag: 700::Helsefag: 800::Helsetjeneste- og helseadministrasjonsforskning: 806 | nob |
dc.subject.nsi | VDP::Medisinske fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 | nob |
dc.subject.nsi | VDP::Medisinske fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 | nob |